上海交通大学学报（医学版）

上海交通大学学报（医学版） >

2021 , Vol. 41 >Issue 3: 386 - 390

DOI: https://doi.org/10.3969/j.issn.1674-8115.2021.03.018

综述

促进脐血造血干/祖细胞植入策略的研究进展

  • 宁柳心 ,
  • 郝思国
展开
  • 上海交通大学医学院附属新华医院血液科，上海 200092
宁柳心（1994—），女，硕士生；电子信箱：nlx2108@163.com。

收稿日期: 2020-01-15

  网络出版日期: 2021-04-06

基金资助

上海申康医院发展中心市级医院临床技能与临床创新三年行动计划项目(16CR1033B)

收起

Progress in researches on improving engraftment of hematopoietic stem/progenitor cells of cord blood

  • Liu-xin NING ,
  • Si-guo HAO
Expand
  • Department of Hematology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

Received date: 2020-01-15

  Online published: 2021-04-06

Supported by

Three-year Action Plan for Clinical Skills and Clinical Innovation in Municipal Hospitals of Shanghai Shenkang Hospital Development Center(16CR1033B)

Fold

摘要

脐血移植（cord blood transplantation，CBT）已广泛地应用于儿童及成人恶性及非恶性血液病的治疗。与其他来源的造血干/祖细胞移植相比，行CBT后造血系统及免疫系统重建较缓慢且存在一定的植入失败率，从而增加了患者感染等导致的移植相关死亡率。因此，如何促进脐血造血干/祖细胞的植入是CBT多年来研究的热点。该文就近年来在促进脐血造血干/祖细胞植入策略的研究进展方面作一综述。

关键词： 脐血移植; 造血干/祖细胞; 体外扩增; 植入; 归巢

本文引用格式

宁柳心 , 郝思国 . 促进脐血造血干/祖细胞植入策略的研究进展[J]. 上海交通大学学报（医学版）, 2021 , 41(3) : 386 -390 . DOI: 10.3969/j.issn.1674-8115.2021.03.018

Abstract

Cord blood transplantation (CBT) has been widely used in the treatment of hematologic malignancies and non-malignant hematologic diseases both in children and adults. Compared with other sources of hematopoietic stem/progenitor cell (HSPC) transplantation, CBT has a higher rate of engraftment failure and delayed hematopoietic system and immune system recovery, thereby increasing the mortality caused by infection and other transplant-related complications. Therefore, how to promote the engraftment of cord blood HSPC has been a hot spot in CBT for many years. The article reviews the latest advances in the strategies to improve the engraftment of HSPC of cord blood.

Key words： cord blood transplantation (CBT); hematopoietic stem/progenitor cell (HSPC); in vitro expansion; engraftment; homing

参考文献

1 Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling[J]. N Engl J Med, 1989, 321(17): 1174-1178.
2 Milano F, Appelbaum FR, Delaney C. Cord-blood transplantation in patients with minimal residual disease[J]. N Engl J Med, 2016, 375(22): 2204-2205.
3 Hiwarkar P, Qasim W, Ricciardelli I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells[J]. Blood, 2015, 126(26): 2882-2891.
4 Mayani H, Wagner JE, Broxmeyer HE. Cord blood research, banking, and transplantation: achievements, challenges, and perspectives[J]. Bone Marrow Transplant, 2019, 55(1): 48-61.
5 Barker JN, Weisdorf DJ, DeFor TE, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy[J]. Blood, 2005, 105(3): 1343-1347.
6 Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units[J]. Blood, 2009, 114(19): 4293-4299.
7 Ruggeri A, Sanz G, Bittencourt H, et al. Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT[J]. Leukemia, 2014, 28(4): 779-786.
8 Wagner JE Jr, Eapen M, Carter S, et al. One-unit versus two-unit cord-blood transplantation for hematologic cancers[J]. N Engl J Med, 2014, 371(18): 1685-1694.
9 Michel G, Galambrun C, Sirvent A, et al. Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome[J]. Blood, 2016, 127(26): 3450-3457.
10 Dahlberg A, Woo S, Delaney C, et al. Notch-mediated expansion of cord blood progenitors: maintenance of transcriptional and epigenetic fidelity[J]. Leukemia, 2015, 29(9): 1948-1951.
11 Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution[J]. Nat Med, 2010, 16(2): 232-236.
12 Peled T, Mandel J, Goudsmid RN, et al. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine[J]. Cytotherapy, 2004, 6(4): 344-355.
13 de Lima M, McMannis J, Gee A, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase Ⅰ/Ⅱ clinical trial[J]. Bone Marrow Transplant, 2008, 41(9): 771-778.
14 Stiff PJ, Montesinos P, Peled T, et al. Cohort-controlled comparison of umbilical cord blood transplantation using carlecortemcel-L, a single progenitor-enriched cord blood, to double cord blood unit transplantation[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1463-1470.
15 Peled T, Shoham H, Aschengrau D, et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment[J]. Exp Hematol, 2012, 40(4): 342-355.
16 Horwitz ME, Wease S, Blackwell B, et al. Phase Ⅰ/Ⅱ study of stem-cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide[J]. J Clin Oncol, 2019, 37(5): 367-374.
17 Horwitz ME, Chao NJ, Rizzieri DA, et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment[J]. J Clin Invest, 2014, 124(7): 3121-3128.
18 Anand S, Thomas S, Hyslop T, et al. Transplantation of ex vivo expanded umbilical cord blood (NiCord) decreases early infection and hospitalization[J]. Biol Blood Marrow Transplant, 2017, 23(7): 1151-1157.
19 Leung A, Zulick E, Skvir N, et al. Notch and aryl hydrocarbon receptor signaling impact definitive hematopoiesis from human pluripotent stem cells[J]. Stem Cells, 2018, 36(7): 1004-1019.
20 Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells[J]. Science, 2010, 329(5997): 1345-1348.
21 Wagner JE Jr, Brunstein CG, Boitano AE, et al. Phase Ⅰ/Ⅱ trial of StemRegenin-1 expandedumbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft[J]. Cell Stem Cell, 2016, 18(1): 144-155.
22 Robinson SN, Simmons PJ, Yang H, et al. Mesenchymal stem cells in ex vivo cord blood expansion[J]. Best Pract Res Clin Haematol, 2011, 24(1): 83-92.
23 Zhao D, Liu L, Chen Q, et al. Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells[J]. Stem Cell Res Ther, 2018, 9(1): 158.
24 Lo Iacono M, Russo E, Anzalone R, et al. Wharton's jelly mesenchymal stromal cells support the expansion of cord blood-derived CD34+ cells mimicking a hematopoietic niche in a direct cell-cell contact culture system[J]. Cell Transplant, 2018, 27(1): 117-129.
25 郝思国, 孙关林, 邬维礼, 等. 骨髓基质细胞共培养体系促进人脐血CD133+细胞的体外扩增[J]. 中华器官移植杂志, 2005, 26(1): 28-32.
26 de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture[J]. N Engl J Med, 2012, 367(24): 2305-2315.
27 Baron F, Ruggeri A, Nagler A. Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications[J]. Expert Rev Hematol, 2016, 9(3): 297-314.
28 Thompson PA, Rezvani K, Hosing CM, et al. Umbilical cord blood graft engineering: challenges and opportunities[J]. Bone Marrow Transplant, 2015, 50(): S55-S62.
29 Frassoni F, Gualandi F, Podesta M, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase Ⅰ/Ⅱ study[J]. Lancet Oncol, 2008, 9(9): 831-839.
30 Murata M, Maeda Y, Masuko M, et al. Phase Ⅱ study of intrabone single unit cord blood transplantation for hematological malignancies[J]. Cancer Sci, 2017, 108(8): 1634-1639.
31 Okada M, Tasaka T, Ikegame K, et al. A prospective multicenter phase Ⅱ study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning[J]. Eur J Haematol, 2018, 100(4): 335-343.
32 Bonifazi F, Dan E, Labopin M, et al. Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study[J]. Bone Marrow Transplant, 2019, 54(5): 717-725.
33 Hagedorn EJ, Durand EM, Fast EM, et al. Getting more for your marrow: boosting hematopoietic stem cell numbers with PGE2[J]. Exp Cell Res, 2014, 329(2): 220-226.
34 Hoggatt J, Singh P, Sampath J, et al. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation[J]. Blood, 2009, 113(22): 5444-5455.
35 Cutler C, Multani P, Robbins D, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation[J]. Blood, 2013, 122(17): 3074-3081.
36 van Besien K, Hari P, Zhang MJ, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival[J]. Haematologica, 2016, 101(5): 634-643.
37 Hsu J, Artz A, Mayer SA, et al. Combined haploidentical and umbilical cord blood allogeneic stem cell transplantation for high-risk lymphoma and chronic lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2018, 24(2): 359-365.
Options
文章导航

/

〈 〉